ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member 1

ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member 1

Pathway Diagram

```mermaid
flowchart TD
ABCB1["ABCB1<br/>P-glycoprotein<br/>Drug Efflux Pump"]

BBB["Blood-Brain Barrier<br/>Drug Transport"]
TFR1["TFR1<br/>Transferrin Receptor"]
LRP1["LRP1<br/>Low-density Lipoprotein<br/>Receptor-related Protein"]

DrugEfflux["Drug Efflux<br/>Mechanism"]
Neuroprotection["Neuroprotective<br/>Drug Clearance"]

Alzheimer["Alzheimer's<br/>Disease"]
Parkinson["Parkinson's<br/>Disease"]
ALS["Amyotrophic<br/>Lateral Sclerosis"]
MS["Multiple<br/>Sclerosis"]
Dementia["Dementia"]

Inflammation["Neuroinflammation"]
Toxicity["Neurotoxin<br/>Accumulation"]

TherapeuticTarget["Therapeutic<br/>Target for<br/>Drug Delivery"]

ABCB1 -->|"regulates"| BBB
ABCB1 -->|"activates"| DrugEfflux
DrugEfflux -->|"leads to"| Neuroprotection

TFR1 -->|"interacts with"| ABCB1
LRP1 -->|"interacts with"| ABCB1

ABCB1 -->|"associated with"| Alzheimer
ABCB1 -->|"activates"| Parkinson
ABCB1 -->|"protects against"| ALS
ABCB1 -->|"therapeutic target"| MS
ABCB1 -->|"therapeutic target"| Dementia

ABCB1 -->|"reduces"| Inflammation
ABCB1 -->|"prevents"| Toxicity

BBB -->|"controls"| TherapeuticTarget
Neuroprotection -->|"reduces"| Alzheimer
Neuroprotection -->|"reduces"| Parkinson

Toxicity -->|"contributes to"| Alzheimer
Toxicity -->|"contributes to"| Parkinson
Inflammation -->|"promotes"| MS

style ABCB1 fill:#006494
style Neuroprot

ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member 1

Pathway Diagram

<div class="infobox infobox-gene">
<h3>ABCB1 (MDR1)</h3>
<table>
<tr><td><strong>Full Name</strong></td><td>ATP Binding Cassette Subfamily B Member 1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ABCB1 (MDR1, PGP)</td></tr> [@kortekaas2005]
<tr><td><strong>Chromosomal Location</strong></td><td>7q21.12</td></tr> [@lscher2005]
<tr><td><strong>NCBI Gene ID</strong></td><td>[5243](https://www.ncbi.nlm.nih.gov/gene/5243)</td></tr> [@vogelgesang2002]
<tr><td><strong>OMIM</strong></td><td>[171050](https://omim.org/entry/171050)</td></tr> [@bartels2008]
<tr><td><strong>Ensembl</strong></td><td>[ENSG00000085563](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000085563)</td></tr> [@brenn2011]
<tr><td><strong>UniProt (Protein)</strong></td><td>[P08183 (P-glycoprotein)](https://www.uniprot.org/uniprot/P08183)</td></tr> [@callaghan2014]
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis)</td></tr>
</table>
</div>

Overview

ABCB1 (ATP Binding Cassette Subfamily B Member 1), also known as MDR1 (multidrug resistance protein 1) or P-glycoprotein (P-gp), encodes a 170 kDa ATP-dependent efflux transporter that is a critical component of the [blood-brain barrier](/mechanisms/blood-brain-barrier). P-glycoprotein is the most extensively studied drug efflux transporter at the [BBB](/entities/blood-brain-barrier) and plays a central role in limiting brain penetration of xenobiotics, toxins, and therapeutic agents. Its dysfunction has been implicated in multiple neurodegenerative diseases, where impaired efflux contributes to both toxic accumulation and therapeutic failure.

Gene Structure and Expression

ABCB1 spans approximately 209 kb on chromosome 7q21.12 and contains 29 exons encoding a 1,280 amino acid protein. The gene produces two major transcript variants through alternative splicing. ABCB1 expression is regulated by multiple transcription factors including [PXR](/genes/nr1i2), [CAR](/genes/nr1i3), and [NF-κB](/mechanisms/nf-kb-pathway), with promoter methylation serving as an additional regulatory mechanism.

In the brain, ABCB1 is predominantly expressed at the luminal (blood-facing) membrane of brain capillary endothelial cells, where it functions as the primary efflux pump of the [blood-brain barrier](/mechanisms/blood-brain-barrier). Lower levels of expression are detected in astrocyte end-feet, [microglia](/cell-types/microglia-neuroinflammation), and [neurons](/entities/neurons). Expression is highest in the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus), with moderate levels in the cerebellum and brainstem. The [Allen Brain Atlas](https://human.brain-map.org/) confirms enriched endothelial expression across all brain regions.

Protein Function and Mechanism

P-glycoprotein is a member of the ABC transporter superfamily and functions as an ATP-dependent efflux pump with remarkably broad substrate specificity. The protein contains two transmembrane domains (TMDs), each with six transmembrane helices forming a drug-binding cavity, and two nucleotide-binding domains (NBDs) that hydrolyze ATP to power substrate translocation.

Transport Mechanism

The transport cycle follows an alternating access model:

P-glycoprotein recognizes an extraordinarily diverse range of substrates, typically hydrophobic or amphipathic compounds with molecular weights of 300–4,000 Da. This includes many CNS drugs (antiepileptics, antidepressants, antipsychotics, opioids), chemotherapeutics, and endogenous substrates including [amyloid-beta](/proteins/amyloid-beta) peptides.

Amyloid-Beta Transport

A critical function in neurodegeneration is the transport of [amyloid-beta (Aβ)](/proteins/amyloid-beta) across the BBB. P-glycoprotein mediates the efflux of both Aβ40 and Aβ42 from the brain parenchyma into the bloodstream. This clearance pathway operates in concert with [LRP1](/genes/lrp1)-mediated transcytosis and represents a major route for Aβ elimination. Impaired P-gp function leads to reduced Aβ clearance and accelerated amyloid deposition, directly linking ABCB1 dysfunction to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis.

Disease Associations

Alzheimer's Disease

Multiple lines of evidence connect ABCB1 to [Alzheimer's disease](/diseases/alzheimers-disease):

• Reduced expression: P-gp expression and function decline with age and are further reduced in AD brains, particularly in hippocampal and cortical capillaries. PET imaging studies using 11C-verapamil demonstrate increased BBB permeability to P-gp substrates in AD patients
• Amyloid clearance deficiency: Decreased P-gp–mediated Aβ efflux contributes to cerebral amyloid accumulation. ABCB1 knockout mice show increased brain Aβ levels and accelerated plaque deposition when crossed with [APP](/entities/app-protein) transgenic models
• Genetic associations: The C3435T (rs1045642) polymorphism has been associated with AD risk in multiple populations, though effect sizes are modest and population-dependent
• Therapeutic implications: Restoring P-gp function represents a potential therapeutic strategy. PXR agonists and [LXR](/genes/nr1h3) ligands that upregulate ABCB1 expression have shown efficacy in reducing brain Aβ in preclinical models

Parkinson's Disease

P-glycoprotein dysfunction at the BBB may contribute to [Parkinson's disease](/diseases/parkinsons-disease) by:

• Failing to exclude environmental neurotoxins (pesticides, herbicides) that are P-gp substrates
• Reduced clearance of [α-synuclein](/proteins/alpha-synuclein) aggregates
• PET studies showing decreased P-gp function in the midbrain of early PD patients
• The C3435T variant showing modest association with PD risk in some populations

Pharmacoresistance in Neurological Diseases

P-gp overexpression in epileptic brain tissue contributes to antiepileptic drug resistance by limiting drug penetration to seizure foci. This "transporter hypothesis" of pharmacoresistance extends to treatment-resistant depression and other CNS disorders.

Common Variants

| Variant | rsID | Consequence | Clinical Significance |
|---------|------|-------------|----------------------|
| C3435T | rs1045642 | Synonymous (Ile1145Ile) | Altered mRNA stability, reduced P-gp expression; associated with AD/PD risk |
| G2677T/A | rs2032582 | Ala893Ser/Thr | Altered substrate specificity and transport kinetics |
| C1236T | rs1128503 | Synonymous (Gly412Gly) | Haplotype effects on protein folding and function |
| T-129C | rs3213619 | Promoter variant | Altered transcription; associated with drug response variability |

The C3435T–G2677T–C1236T haplotype is the most extensively studied, with the TTT haplotype associated with reduced P-gp expression and function.

Therapeutic Implications

Enhancing P-gp Function for Neuroprotection

• PXR/LXR agonists: Rifampin, St. John's wort (hyperforin), and synthetic LXR ligands upregulate ABCB1 expression and enhance Aβ clearance
• Thiethylperazine: Identified as a P-gp inducer that reduces brain Aβ in mouse models
• Exercise: Physical activity increases cerebrovascular P-gp expression, potentially contributing to the neuroprotective effects of exercise

Inhibiting P-gp for Drug Delivery

• First-generation inhibitors: Verapamil, cyclosporine A — limited by off-target effects
• Third-generation inhibitors: Tariquidar, elacridar — more selective but clinical utility limited by systemic toxicity
• Nanoparticle strategies: P-gp–evading nanocarriers for targeted CNS drug delivery

Biomarker Applications

• 11C-verapamil PET imaging as a biomarker of BBB P-gp function
• Potential use in monitoring BBB integrity decline in preclinical AD

Expression Profile

P-glycoprotein shows the following expression pattern relevant to neurodegeneration:

• Brain endothelium: Highest expression at BBB (luminal membrane)
• Choroid plexus: Blood-CSF barrier expression
• [Astrocytes](/entities/astrocytes): Lower expression at end-feet processes
• Microglia: Inducible expression during neuroinflammation
• Peripheral: Liver, kidney, intestine (drug disposition)

Mechanism Map

See Also

• [ABCG2](/genes/abcg2) — BCRP efflux transporter at BBB
• [LRP1](/genes/lrp1) — Aβ transcytosis receptor
• [RAGE](/genes/ager) — Aβ influx receptor
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier) — BBB structure and function
• [Amyloid-Beta](/proteins/amyloid-beta) — Aβ peptide clearance
• [SLC2A1](/genes/slc2a1) — GLUT1 glucose transporter at BBB
• [CLDN5](/genes/cldn5) — Claudin-5 tight junction protein

External Links

• [NCBI Gene: ABCB1](https://www.ncbi.nlm.nih.gov/gene/5243)
• [UniProt: P08183](https://www.uniprot.org/uniprot/P08183)
• [GeneCards: ABCB1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCB1)
• [OMIM: 171050](https://omim.org/entry/171050)
• [Allen Brain Atlas: ABCB1](https://human.brain-map.org/)
• [PharmGKB: ABCB1](https://www.pharmgkb.org/gene/PA267)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: TFR1, LRP1, CAV1, ABCB1